

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/635,908
Applicant : Reinier LH Bolhuis *et al.*
Filed : August 7, 2003
TC/A.U. : 1643
Examiner : Parithosh K. Tungaturthi

Docket No. : 2923-552
Customer No. : 6449
Confirmation No. : 7844

DECLARATION

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


Sir:

I, Gerd Ritter, declare as follows.

1. I am a coinventor of a published U.S. Pat. Appl. No. 2003/0040027 (hereinafter "the '027 application").
2. I am a coauthor of a publication, Ritter et al., Cancer Research. 61, 6851-6859, September 15, 2001 (hereinafter "Ritter et al."). I am the author to whom all request for reprints of the publication was to be addressed.
3. I understand that the G250 monoclonal antibody was mentioned in the '027 application as having been "purchased" in Example 1 under paragraph [0013]. However, the G250 monoclonal antibody was not "purchased," but was instead "produced" by Sven Warnaar of Centocor, as described on p. 6851 in Ritter et al.
4. In a 1996 agreement, Centocor and the Ludwig Institute for Cancer Research (LICR) agreed that Centocor, through Sven Warnaar, would deliver

antibodies, including G250, to LICR. LICR allocated some of the G250 antibody to me to conduct the studies described in the '027 application and in Ritter et al. This allotment of G250 was used only by me and members of my team who were under my control and supervision.

5. I state that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.



Dr. Gerd Ritter

6/18/08
Date